Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
Korsana crosses into crowded Alzheimer's field with $175M and anti-amyloid antibody
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.